Novo Nordisk STEP Young: 40.4% below threshold

Novo Nordisk said on September 7 that its Phase 3 STEP Young trial showed 40.4% of children ages 6 to under 12 with obesity moved below the obesity threshold after 68 weeks on once-weekly semaglutide plus lifestyle intervention, compared with 0% on placebo. The Danish drugmaker said the study tested semaglutide alongside reduced-calorie diet and increased physical activity in that age group. The company also said the safety profile was consistent with semaglutide studies in adults and adolescents, while adding that the treatment is not approved for children younger than 12 for obesity. ### What exactly did Novo Nordisk report? Novo Nordisk’s September 7 statement focused on a responder-style endpoint rather than only average weight loss. The company said 40.4% of children treated with semaglutide and lifestyle modification achieved a body mass index below the obesity threshold by week 68, versus none in the placebo group. That is the figure circulating most widely in investor and industry discussion. (novonordisk.com) The 68-week duration fits the broader STEP obesity program design used in several semaglutide studies. In prior STEP protocols for older populations, Novo Nordisk used once-weekly semaglutide 2.4 mg against placebo on top of diet and physical activity over 68 weeks, though the company’s public summary of STEP Young did not, in the material reviewed, spell out all dosing details in the same way. (novonordisk.com) ### Who was studied in STEP Young? STEP Young enrolled children ages 6 to under 12 living with obesity, according to Novo Nordisk’s public summary. That makes it younger than the adolescent population studied in STEP TEENS, which evaluated semaglutide in patients ages 12 to under 18 with overweight or obesity. ClinicalTrials.gov lists a Novo Nordisk study record at NCT05726227, which aligns with the company’s pediatric obesity work in this age range, although the registry page available through search results was not fully readable in the retrieved material. (cdn.clinicaltrials.gov) Based on Novo Nordisk’s release and the trial identifier surfaced in search, STEP Young is the company’s late-stage test of semaglutide in children below age 12. (novonordisk.com) ### Why is “below the obesity threshold” the number people are focusing on? The 40.4% figure translates the trial into a category parents, doctors and investors can recognize: how many children no longer met the obesity cutoff after treatment. Novo Nordisk highlighted that outcome directly in the headline of its release, rather than leading with mean BMI change alone. Industry discussion on X over the last 48 hours repeated that same comparison — 40.4% on semaglutide versus 0% on placebo at 68 weeks — and paired it with the company’s note that the safety profile matched what had been seen in adults and adolescents. (clinicaltrials.gov) Those posts tracked the company’s wording rather than adding independent data. ### What did Novo Nordisk say about safety and approval status? (novonordisk.com) Novo Nordisk said the safety profile in STEP Young was consistent with semaglutide use in adults and adolescents. In prior adolescent STEP TEENS materials, the company described semaglutide as generally well tolerated, with gastrointestinal side effects common in the class and serious medication side effects occurring infrequently. (novonordisk.com) The company also said semaglutide is not approved for obesity treatment in children ages 6 to under 12. That matters because the release reports clinical-trial results, not a regulatory clearance or label expansion. ### How does this fit into Novo Nordisk’s broader semaglutide program? Semaglutide is already a core Novo Nordisk product across diabetes and obesity, and the company has been extending the franchise through adult, adolescent and other obesity-related studies. (novonordisk.com) The adolescent STEP TEENS program previously showed semaglutide reduced BMI and body weight more than placebo in patients ages 12 to under 18. The next concrete step is fuller disclosure. Novo Nordisk’s September 7 release gave top-line Phase 3 data, and additional detail would typically come in a conference presentation, manuscript, regulatory submission or updated trial registry posting. As of September 8, the company’s public materials reviewed here showed the top-line result and the statement that semaglutide remains unapproved for this younger age group. (novonordisk.com) (sciencehub.novonordisk.com)